Background: In this retrospective study, we developed and internally validate a nomogram for predicting 5-year metastasis probability for nonmetastatic extremity osteosarcoma.
introduction Osteosarcoma is a rare bone cancer and has an incidence of only few cases per million person-years on a worldwide basis [1] . Since the introduction of combined systemic chemotherapy, the long-term survival of patients with osteosarcoma has dramatically improved. Unfortunately, despite the numerous clinical trials conducted over several decades, patient survival has not significantly improved. Osteosarcoma has a remarkably heterogeneous clinical behavior. Historically, up to 15% of patients have been reported to be cured by surgery alone [2] . Currently, however, a substantial number of patients eventually succumb to their disease despite all treatment efforts. Clinical staging systems, such as the AJCC classification and Enneking's system, broadly identify risk groups based on initial clinical characteristics, such as tumor grade, size, and presence of skip lesion or metastasis [3, 4] . Clinical stage has been reported to be correlated with survival [5] . In addition to the factors used for clinical staging, several other clinical variables have been correlated with survival, e.g. patient age [6, 7] , tumor site [1] , and response to preoperative chemotherapy [8] , type of surgery [9] , and local recurrence [10] . In addition, serological and molecular markers, such as alkaline phosphatase [11] , P-glycoprotein [12] , CXCR4 [13] , survivin [14] , and ezrin [15] , have been proposed to be useful for predicting response to chemotherapy and prognosis. Nonetheless, these prognostic factors individually have limited utility in terms of predicting survival.
A nomogram is a graphic representation of a statistical model and provides scales for calculating the cumulative effect of weighted variables on the numerical probability of a particular clinical outcome, such as death or recurrence [16] . Furthermore, nomograms have been shown to be superior to more traditional staging systems in a variety of cancers [17] [18] [19] [20] [21] [22] [23] [24] . Nomograms also enable individualized predictions to be made, and therefore, are useful for identifying and stratifying patients at risk who would benefit from aggressive therapy original article or an investigational approach. However, no nomogram has been reported for sarcoma, other than soft tissue sarcoma [25] . The generation of a predictive nomogram for osteosarcoma is difficult, given the rarity of the disease. Moreover, few consistent prognostic factors are known to predict outcome. In the present study, we constructed a nomogram using four independent covariates including two well-known factors (size and histologic response) and two newly identified factors (age and tumor location). We propose that this nomogram enables individualized outcome predictions, which could aid patients, clinicians, and clinical investigators during the treatment decision-making process.
patients and methods

patient cohort
This retrospective analysis included 365 osteosarcoma patients treated at our institute from 1990 to 2003. The inclusion criteria used were as follows: (i) extremity osteosarcoma, (ii) AJCC stage II, (iii) scheduled for neoadjuvant and adjuvant chemotherapy and surgery at our institute, and (iv) more than a 5-year follow-up for event-free patients. The exclusion criteria were as follows: (i) secondary osteosarcoma, (ii) extraskeletal osteosarcoma, and (iii) high-grade surface osteosarcoma. Informed consent was obtained from all patients or legal guardians, as appropriate. This study was approved by the institutional research review board. All patients underwent preoperative chemotherapy, surgery, and postoperative chemotherapy and were followed as described previously [26] . Clinicopathologic variables were recorded and included age, gender, tumor location, maximal tumor diameter on initial magnetic resonance images, histologic subtype, presence of a pathologic fracture, and tumor necrosis rate after chemotherapy. Histologic responses were assessed at time of surgery and recorded as the percentage of tumor necrosis.
creating the nomogram
Multivariate analysis was conducted using Cox proportional hazards regression. The proportional hazards assumption was verified by tests of correlations with time and by examination of residual plots. This Cox model was then used as the basis for the nomogram. All decisions with respect to the grouping of categorical variables were made before modeling. The nomogram was constructed as described by Kattan et al. [16] . Clinicopathological variables included age, tumor location, maximal tumor diameter, and tumor necrosis rate after chemotherapy.
validation of the nomogram
The nomogram was validated in three ways. First, discrimination was quantified using the concordance index (CI), which is the probability, given two randomly drawn patients, that the patient who develops metastasis first has the higher probability on the nomogram. This was calculated by bootstrapping 200 samples from the original 365 patients used to fit the Cox model, and this served as an unbiased measure of the ability of the nomogram to discriminate patients. Secondly, we examined the calibration of the nomogram. This was done by grouping patients with respect to their nomogram-predicted probabilities, and then comparing group means with observed Kaplan-Meier estimates of metastatic probability. Again, 200 bootstrap resamples were used for this activity. Finally, discriminatory power of the nomogram (CI) was compared against that of the AJCC staging system and histologic response. All analyses were conducted using S-plus 2000 Professional software (Statistical Sciences, Seattle, WA).
results
Descriptive statistics for this cohort are summarized in Table 1 . Of the 365 patients, 241 were male (66.0%) and 124 female (34.0%), of overall median age 16 years (range 3-63 years). Based on the AJCC staging system, 141 patients (38.6%) had a stage IIA tumor and 224 (61.4%) had a stage IIB tumor.
The primary end point was time to metastasis. Metastasisfree interval was defined as time between date of diagnosis to last visit or the date when distant metastasis was found. The median follow-up time for all patients was 79 months [95% confidence interval (CI) 76-82 months]. During follow-up, metastasis occurred in 146 patients (40.0%), and the estimated 5-year metastasis-free survival rate, as calculated by the KaplanMeier method, was 60.0% (95% CI 57.4%-62.6%; Figure 1A ). Metastases were located in lung in 114 patients, bone in 18, lung and bone in eight, and in other locations in six. Metastasis-free survivals by AJCC stage grouping and histologic response are shown in Figure 1B and C.
Univariate analysis was carried out to identify patient characteristics correlated with survival. The univariate Cox model identified patient age at diagnosis, maximal tumor diameter, tumor location in humerus, and tumor necrosis rate after chemotherapy as being associated with metastasis-free survival, but no such association was found for gender, histologic subtype, or pathologic fracture (Table 2) . Cox proportional hazards modeling, a form of multivariate regression analysis, was carried out to examine relations between independent variables and metastasis-free survival. All significant variables identified by univariate analysis were used to develop the multivariable model. Table 2 indicates the best model after eliminating variables that were not statistically significant. A nomogram was developed to predict metastasis based on the four independent covariates identified by the Cox proportional hazards model. The nomogram is presented in Figure 2 . The contribution of each covariate to the total point can be visually appreciated and was potentially greatest for tumor location, tumor necrosis rate, followed by maximal tumor diameter and age. Median total points for the 365 patients used to fit the multivariable Cox model was 180 (range 24-265), and the first and third quartiles were 145 and 204, respectively. The concordance index for the model was 0.78. The calibration curve illustrated in Figure 3 shows how predictions from the nomogram compare with the actual outcomes of the 365 patients ( Figure 3) . The dashed line 
discussion
Nomograms are being progressively more accepted as models in which known prognostic factors can be combined and used for risk prediction in cancer [27] . One advantage of nomograms is that they are weighted models comprised of independent prognostic factors, which provide an appreciation of the magnitude of impacts of individual factors on outcome probability. In the present study, we developed and internally validated a nomogram for predicting 5-year metastasis probability after surgery and chemotherapy for nonmetastatic extremity osteosarcoma. The nomogram predicts with a concordance index of 0.78, and it is more predictive than histologic response or AJCC stage alone. The distribution of nomogram-based metastasis probability was wide in AJCC stage IIB disease. For example, the average 5-year metastasis probability for a stage IIB patient in this study was 0.50, but ranged from 0.16 to 0.98 by nomogram prediction. Under the current standard protocol, all patients are given the same treatment regardless of their characteristics, and they are expected to have similar prognoses based on considerations of AJCC stage or histologic response. Currently, tumor necrosis rate after preoperative chemotherapy (histologic response) is generally accepted to be the strongest prognostic factor for patients without metastases at initial diagnosis [1] . Several cutoff values have been used to categorize or stratify continuous value of necrosis rates into categorical variable. The Salzer-Kuntschik system adopted a six-grade scale [28] , while the Huvos' system adopted a fourgrade scale [29] . In both systems, the most widely accepted cutoff point for a favorable or unfavorable response to chemotherapy was 90% necrosis. In this study, we found a significant difference in metastasis probability among the four Huvos' grades. In order to predict outcome at initial diagnosis, we attempted to construct another nomogram based on variables excluding tumor necrosis rate. However, this nomogram showed no better predictability than AJCC staging (data not shown).
In the present study, tumor size was found to be a key prognostic factor, and in the newly revised AJCC staging system, stages I and II are subdivided into A and B categories based on tumor size [3] . Several previous studies have assessed the prognostic significance of tumor size using different parameters, e.g. absolute tumor volumes >60 [30] , 150 [31] , 200 [6] , and 300 ml [7] and linear sizes >8 [32] , 9 [12] , and 10 cm [33] . In this study, we divided the cohort into smaller subgroups based on maximal tumor size and found that two cutoff points (6 cm 8 cm) influenced metastasis probability. original article
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Tumor site is also a potentially significant variable, and it is widely accepted that pelvic and vertebral osteosarcomas have poor outcomes [1] . In extremity osteosarcoma, tumors of distal upper limb are associated with better survival [34] , whereas tumors in proximal femur or humerus have been reported to have poorer prognoses than those on the sides of knee joints, though these findings are still disputed [1] . In our cohort, tumors at the proximal humerus had a significantly poorer prognosis than tumors at the distal femur, proximal tibia, or proximal femur. Furthermore, other locations, such as radius, ulna, hand, and foot, showed remarkably better outcomes than either side of knee despite the small number of cases enrolled.
The pattern of prognosis by age showed a tendency toward unfavorable outcomes in patients both younger and older than adolescents. It has been consistently reported that patients over 40 years have a poor outcome [7, 35] . However, conflicting results have been reported for younger patients. In previous studies, we confirmed a poor outcome in both older patients (age > 40) and in subgroup of patients undergoing growth spurt (12-15 year) [36, 37] . Based on the findings of these previous studies, we used three age categories and confirmed the statistical significance of age; however, external validation is required.
Several limitations of our study require consideration. First, our nomogram was constructed based on data obtained at a single institute on osteosarcoma patients, and therefore, the total number of patients enrolled was relatively small. The devised nomogram was internally validated during the course of this study, but it should be validated in a large number of patients at multiple institutions. Furthermore, it should be borne in mind that prediction by nomogram is not perfect, though it represents an improvement over conventional tools, such as histologic response or AJCC stage. Secondly, we included only patients with nonmetastatic high-grade extremity osteosarcoma (AJCC stage II), and thus, this devised nomogram cannot be applied to patients with other AJCC stages. Thirdly, the nomogram relies on postoperative variables (e.g. histologic response); therefore, it is not a suitable preoperative patient-counseling tool. Finally, we did not include some known prognostic factors, such as the level of alkaline phosphatase and lactate dehydrogenase, because missing data would have reduced statistical power. Furthermore, it is likely that the inclusion of these variables would improve the predictive ability of the nomogram.
In conclusion, we devised a nomogram that predicts metastasis after neo-adjuvant chemotherapy and surgery for Annals of Oncology original article nonmetastatic osteosarcoma. In addition, the devise nomogram improves on estimates provided by the current AJCC staging system or by tumor necrosis rate to preoperative chemotherapy. Furthermore, the nomogram allows individualized risk assessments to be made and could be used as the basis for risk-adapted therapy.
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